J Cancer 2019; 10(27):6813-6821. doi:10.7150/jca.35489

Research Paper

Systematic Identification of Multi Omics-based Biomarkers in KEAP1 Mutated TCGA Lung Adenocarcinoma

Akhileshwar Namani1, Zhaohong Zheng2, Xiu Jun Wang2, Xiuwen Tang1✉

1. Department of Thoracic Surgery and Department of Biochemistry of the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, PR China;
2. Department of Pharmacology, and Cancer Institute, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, PR China.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Citation:
Namani A, Zheng Z, Wang XJ, Tang X. Systematic Identification of Multi Omics-based Biomarkers in KEAP1 Mutated TCGA Lung Adenocarcinoma. J Cancer 2019; 10(27):6813-6821. doi:10.7150/jca.35489. Available from http://www.jcancer.org/v10p6813.htm

File import instruction

Abstract

Mutations in KEAP1 and/or NRF2 genes have been identified across many cancers and the dysregulation of the NRF2 pathway due to these mutations leads to drug and radioresistance in several cancers. Identification of biomarkers associated with these mutations allows the researchers and clinicians to identify the personalized medicine and quicker diagnosis. In this current study, we carried out an integrated, multi-omics, multi-database analysis of exome, transcriptomics data's of KEAP1 mutated TCGA- Lung adenocarcinoma (LUAD) patients against non-mutated counterparts. Finally, we discovered the gene signature associated with KEAP1 mutations, prognostic genes which were highly correlated with the upregulation of the NRF2 pathway in the KEAP1 mutated LUAD patients. Our finding might be useful to identify the early diagnosis of KEAP1 mutated LUAD patients.

Keywords: TCGA-Lung adenocarcinoma, KEAP1 mutations, NRF2 biomarkers, gene signature